Fermented dairy products and postbiotics
DOI: 10.32364/2618-8430-2023-6-4-15
A.I. Khavkin1,2, T.A. Kovtun3
1Moscow Region Research Clinical Institute of Childhood, Moscow, Russian Federation
2Veltishchev Institute, Moscow, Russian Federation
3Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
The gastrointestinal tract (GIT) is a complex, multifunctional system where immune, endocrine, and nerve cells affecting the body functioning are localized. There live more than 100 trillion microorganisms forming an extracorporeal organ collectively called the intestinal microbiota. It has been proven that a balanced microbial community contributes to the body safety. In this context, special attention is paid to the tactics aimed at maintaining the microbiota in an eubiotic state. The most important among them is an adequate nutrition that provides the body with wholesome nutrients. Enriched baby food products are of great interest, since the child's body is most susceptible to the positive effects of nutritional factors. The use of fermented milk products enriched with prebiotics, probiotics and postbiotics (as a result of the probiotic microorganisms metabolism) in children's nutrition seems to be an extremely promising therapeutic and preventive tactics in clinical pediatrics.
This article analyzes numerous aspects concerning the interaction of metabolic products and microbiota components with the immune system, as well as their effect on the body as a whole. The article also presents the results of our studies on the effect of enriched fermented milk products included in the child's nutrition on his health.
Keywords: microbiota, microbiome, immune system, probiotics, postbiotics, nutraceuticals.
For citation: Khavkin A.I., Kovtun T.A. Fermented dairy products and postbiotics. Russian Journal of Woman and Child Health. 2023;6(4):417–424 (in Russ.). DOI: 10.32364/2618-8430-2023-6-4-15.
About the authors:
Anatolii I. Khavkin — Dr. Sc. (Med.), Professor, Head of the A.V. Mazurin Department of Gastroenterology and Nutrition, Moscow Region Research Clinical Institute of Childhood; 62, Bolshaya Serpukhovskaya str., Moscow, 115093, Russian Federation; Chief Researcher, Veltishchev Institute; 2, Taldomskaya str., Moscow, 125412, Russian Federation; ORCID iD 0000-0001-7308-7280.
Tatyana A. Kovtun — C. Sc. (Med.), Senior Researcher of the Department of Scientific Foundations of Nutrition and Nutritional and Metabolic Therapy, pediatrician of the Nutritional Support Group, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology; 1, Samory Mashela str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-0303-6899. Contact information: Anatoly I. Khavkin, e-mail: khavkin@nikid.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 10.10.2023.
Revised 02.11.2023.
Accepted 28.11.2023.
References
1. Rinninella E., Raoul P., Cintoni M. et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms. 2019;7(1):14. DOI: 10.3390/microorganisms7010014.
2. Butel M.J., Waligora-Dupriet A.J., Wydau-Dematteis S. The developing gut microbiota and its consequences for health. J Dev Orig Health Dis. 2018;9(6):590–597. DOI: 10.1017/S2040174418000119.
3. Preveden T., Scarpellini E., Milić N. et al. Gut microbiota changes and chronic hepatitis C virus infection. Expert Rev Gastroenterol Hepatol. 2017;11(9):813–819. DOI: 10.1080/17474124.2017.1343663.
4. Scarpellini E., Basilico M., Rinninella E. et al. Probiotics and gut health. Minerva Gastroenterol (Torino). 2021;67(4):314–325. DOI: 10.23736/S2724-5985.21.02910-7.
5. Jia W., Xie G., Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018;15(2):111–128. DOI: 10.1038/nrgastro.2017.119.
6. Daniali M., Nikfar S., Abdollahi M. Antibiotic resistance propagation through probiotics. Expert Opin Drug Metab Toxicol. 2020;16(12):1207–1215. DOI: 10.1080/17425255.2020.1825682.
7. Żółkiewicz J., Marzec A., Ruszczyński M., Feleszko W. Postbiotics-A Step Beyond Pre- and Probiotics. Nutrients. 2020;12(8):2189. DOI: 10.3390/nu12082189.
8. Liberati A., Altman D.G., Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. DOI: 10.1371/journal.pmed.1000100.
9. Arumugam M., Raes J., Pelletier E. et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174–180. DOI: 10.1038/nature09944.
10. Tap J., Mondot S., Levenez F. et al. Towards the human intestinal microbiota phylogenetic core. Environ Microbiol. 2009;11(10):2574–2584. DOI: 10.1111/j.1462-2920.2009.01982.x.
11. Zhuang L., Chen H., Zhang S. et al. Intestinal Microbiota in Early Life and Its Implications on Childhood Health. Genomics Proteomics Bioinformatics. 2019;17(1):13–25. DOI: 10.1016/j.gpb.2018.10.002.
12. Yatsunenko T., Rey F.E., Manary M.J. et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222–227. DOI: 10.1038/nature11053.
13. Biagi E., Franceschi C., Rampelli S. et al. Gut Microbiota and Extreme Longevity. Curr Biol. 2016;26(11):1480–1485. DOI: 10.1016/j.cub.2016.04.016.
14. Rooks M.G., Garrett W.S. Gut microbiota, metabolites and host immunity. Nat Rev Immunol. 2016;16(6):341–352. DOI: 10.1038/nri.2016.42.
15. Maynard C.L., Elson C.O., Hatton R.D., Weaver C.T. Reciprocal interactions of the intestinal microbiota and immune system. Nature. 2012;489(7415):231–241. DOI: 10.1038/nature11551.
16. Abenavoli L., Scarpellini E., Colica C. et al. Gut Microbiota and Obesity: A Role for Probiotics. Nutrients. 2019;11(11):2690. DOI: 10.3390/nu11112690.
17. Li H.Y., Zhou D.D., Gan R.Y. et al. Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics on Metabolic Diseases Targeting Gut Microbiota: A Narrative Review. Nutrients. 2021;13(9):3211. DOI: 10.3390/nu13093211.
18. Vallianou N., Stratigou T., Christodoulatos G.S. et al. Probiotics, Prebiotics, Synbiotics, Postbiotics, and Obesity: Current Evidence, Controversies, and Perspectives. Curr Obes Rep. 2020;9(3):179–192. DOI: 10.1007/s13679-020-00379-w.
19. Salminen S., Collado M.C., Endo A. et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18(9):649–667. DOI: 10.1038/s41575-021-00440-6.
20. Tsilingiri K., Rescigno M. Postbiotics: what else? Benef Microbes. 2013;4(1):101–107. DOI: 10.3920/BM2012.0046.
21. Aguilar-Toalá J.E., Arioli S., Behare P. et al. Postbiotics — when simplification fails to clarify. Nat Rev Gastroenterol Hepatol. 2021;18(11):825–826. DOI: 10.1038/s41575-021-00521-6.
22. Qin J., Li R., Raes J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65. DOI: 10.1038/nature08821.
23. Amaretti A., di Nunzio M., Pompei A. et al. Antioxidant properties of potentially probiotic bacteria: in vitro and in vivo activities. Appl Microbiol Biotechnol. 2013;97(2):809–817. DOI: 10.1007/s00253-012-4241-7.
24. Khodaii Z., Ghaderian S.M.H., Natanzi M.M. Probiotic Bacteria and their Supernatants Protect Enterocyte Cell Lines fr om Enteroinvasive Escherichia coli (EIEC) Invasion. Int J Mol Cell Med. 2017;6(3):183–189. DOI: 10.22088/acadpub.BUMS.6.3.183.
25. Izuddin W.I., Loh T.C., Foo H.L. et al. Postbiotic L. plantarum RG14 improves ruminal epithelium growth, immune status and upregulates the intestinal barrier function in post-weaning lambs. Sci Rep. 2019;9(1):9938. DOI: 10.1038/s41598-019-46076-0.
26. West C., Stanisz A.M., Wong A., Kunze W.A. Effects of Saccharomyces cerevisiae or boulardii yeasts on acute stress induced intestinal dysmotility. World J Gastroenterol. 2016;22(48):10532–10544. DOI: 10.3748/wjg.v22.i48.10532.
27. Canonici A., Siret C., Pellegrino E. et al. Saccharomyces boulardii improves intestinal cell restitution through activation of the α2β1 integrin collagen receptor. PLoS One. 2011;6(3):e18427. DOI: 10.1371/journal.pone.0018427.
28. Singh P., Saini P. Food and Health Potentials of Exopolysaccharides Derived from Lactobacilli. Microbiol Res J Int. 2017;22:1–14. DOI: 10.9734/mrji/2017/36935.
29. Makino S., Sato A., Goto A. et al. Enhanced natural killer cell activation by exopolysaccharides derived from yogurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1. J Dairy Sci. 2016;99(2):915–923. DOI: 10.3168/jds.2015-10376.
30. Lei X., Zhang H., Hu Z. et al. Immunostimulatory activity of exopolysaccharides from probiotic Lactobacilli casei WXD030 strain as a novel adjuvant in vitro and in vivo. Food Agric Immunol. 2018;29:1086–1105. DOI: 10.1080/09540105.2018.1513994.
31. Li W., Ji J., Chen X. et al. Structural elucidation and antioxidant activities of exopolysaccharides from Lactobacillus helveticus MB2-1. Carbohydr Polym. 2014;102:351–359. DOI: 10.1016/j.carbpol.2013.11.053.
32. Khalil E.S., Abd Manap M.Y., Mustafa S. et al. Probiotic Properties of Exopolysaccharide-Producing Lactobacillus Strains Isolated from Tempoyak. Molecules. 2018;23(2):398. DOI: 10.3390/molecules23020398.
33. Uchida M., Ishii I., Inoue C. et al. Kefiran reduces atherosclerosis in rabbits fed a high cholesterol diet. J Atheroscler Thromb. 2010;17(9):980–988. DOI: 10.5551/jat.4812.
34. Li B., Cai Y., Qi C. et al. Orally administered particulate beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer. Clin Cancer Res. 2010;16(21):5153–5164. DOI: 10.1158/1078-0432.CCR-10-0820.
35. Vetvicka V., Vetvickova J. Glucan supplementation enhances the immune response against an influenza challenge in mice. Ann Transl Med. 2015;3(2):22. DOI: 10.3978/j.issn.2305-5839.2015.01.08.
36. Garai-Ibabe G., Dueñas M.T., Irastorza A. et al. Naturally occurring 2-substituted (1,3)-beta-D-glucan producing Lactobacillus suebicus and Pediococcus parvulus strains with potential utility in the production of functional foods. Bioresour Technol. 2010;101(23):9254–9263. DOI: 10.1016/j.biortech.2010.07.050.
37. Morifuji M., Ichikawa S., Kitade M. et al. Exopolysaccharides from milk fermented by lactic acid bacteria enhance dietary carotenoid bioavailability in humans in a randomized crossover trial and in rats. Am J Clin Nutr. 2020;111(4):903–914. DOI: 10.1093/ajcn/nqaa020.
38. Jesenak M., Urbancek S., Majtan J. et al. β-Glucan-based cream (containing pleuran isolated from pleurotus ostreatus) in supportive treatment of mild-to-moderate atopic dermatitis. J Dermatolog Treat. 2016;27(4):351–354. DOI: 10.3109/09546634.2015.1117565.
39. Kullisaar T., Zilmer M., Mikelsaar M. et al. Two antioxidative lactobacilli strains as promising probiotics. Int J Food Microbiol. 2002;72(3):215–224. DOI: 10.1016/s0168-1605(01)00674-2.
40. Kim H.S., Chae H.S., Jeong S.G. et al. In vitro Antioxidative Properties of Lactobacilli. Asian-Australas J Anim Sci. 2005;19:262–265. DOI: 10.5713/ajas.2006.262.
41. Izuddin W.I., Humam A.M., Loh T.C. et al. Dietary Postbiotic Lactobacillus plantarum Improves Serum and Ruminal Antioxidant Activity and Upregulates Hepatic Antioxidant Enzymes and Ruminal Barrier Function in Post-Weaning Lambs. Antioxidants (Basel). 2020;9(3):250. DOI: 10.3390/antiox9030250.
42. LeBlanc J.G., del Carmen S., Miyoshi A. et al. Use of superoxide dismutase and catalase producing lactic acid bacteria in TNBS induced Crohn's disease in mice. J Biotechnol. 2011;151(3):287–293. DOI: 10.1016/j.jbiotec.2010.11.008.
43. Moser S.A., Savage D.C. Bile salt hydrolase activity and resistance to toxicity of conjugated bile salts are unrelated properties in lactobacilli. Appl Environ Microbiol. 2001;67(8):3476–3480. DOI: 10.1128/AEM.67.8.3476-3480.2001.
44. Allain T., Chaouch S., Thomas M. et al. Bile Salt Hydrolase Activities: A Novel Target to Screen Anti-Giardia Lactobacilli? Front Microbiol. 2018;9:89. DOI: 10.3389/fmicb.2018.00089.
45. Van Langevelde P., van Dissel J.T., Ravensbergen E. et al. Antibiotic-induced release of lipoteichoic acid and peptidoglycan from Staphylococcus aureus: quantitative measurements and biological reactivities. Antimicrob Agents Chemother. 1998;42(12):3073–3078. DOI: 10.1128/AAC.42.12.3073.
46. Kaji R., Kiyoshima-Shibata J., Nagaoka M. et al. Bacterial teichoic acids reverse predominant IL-12 production induced by certain lactobacillus strains into predominant IL-10 production via TLR2-dependent ERK activation in macrophages. J Immunol. 2010;184(7):3505–3513. DOI: 10.4049/jimmunol.0901569.
47. Zadeh M., Khan M.W., Goh Y.J. et al. Induction of intestinal pro-inflammatory immune responses by lipoteichoic acid. J Inflamm (Lond). 2012;9:7. DOI: 10.1186/1476-9255-9-7.
48. Schauber J., Gallo R.L. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol. 2009;124(3 Suppl 2):R13–18. DOI: 10.1016/j.jaci.2009.07.014.
49. Wang Z., MacLeod D.T., Di Nardo A. Commensal bacteria lipoteichoic acid increases skin mast cell antimicrobial activity against vaccinia viruses. J Immunol. 2012;189(4):1551–1558. DOI: 10.4049/jimmunol.1200471.
50. Okamoto M., Ohe G., Oshikawa T. et al. Enhancement of anti-cancer immunity by a lipoteichoic-acid-related molecule isolated from a penicillin-killed group A Streptococcus. Cancer Immunol Immunother. 2001;50(8):408–416. DOI: 10.1007/s002620100207.
51. Lebeer S., Claes I.J., Vanderleyden J. Anti-inflammatory potential of probiotics: lipoteichoic acid makes a difference. Trends Microbiol. 2012;20(1):5–10. DOI: 10.1016/j.tim.2011.09.004.
52. Lee C., Kim B.G., Kim J.H. et al. Sodium butyrate inhibits the NF-kappa B signaling pathway and histone deacetylation, and attenuates experimental colitis in an IL-10 independent manner. Int Immunopharmacol. 2017;51:47–56. DOI: 10.1016/j.intimp.2017.07.023.
53. Lührs H., Gerke T., Müller J.G. et al. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol. 2002;37(4):458–466. DOI: 10.1080/003655202317316105.
54. Kasahara K., Krautkramer K.A., Org E. et al. Interactions between Roseburia intestinalis and diet modulate atherogenesis in a murine model. Nat Microbiol. 2018;3(12):1461–1471. DOI: 10.1038/s41564-018-0272-x.
55. Aoki R., Kamikado K., Suda W. et al. A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation. Sci Rep. 2017;7:43522. DOI: 10.1038/srep43522.
56. Frost G., Sleeth M.L., Sahuri-Arisoylu M. et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun. 2014;5:3611. DOI: 10.1038/ncomms4611.
57. Fukuda S., Toh H., Taylor T.D. et al. Acetate-producing bifidobacteria protect the host from enteropathogenic infection via carbohydrate transporters. Gut Microbes. 2012;3(5):449–454. DOI: 10.4161/gmic.21214.
58. Bush R.S., Milligan L.P. Study of the mechanism of inhibition of ketogenesis by propionate in bovine liver. Can J Anim Sci. 1971;51:121–127. DOI: 10.4141/CJAS71-016.
59. Tedelind S., Westberg F., Kjerrulf M., Vidal A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol. 2007;13(20):2826–2832. DOI: 10.3748/wjg.v13.i20.2826.
60. Melbye P., Olsson A., Hansen T.H. et al. Short-chain fatty acids and gut microbiota in multiple sclerosis. Acta Neurol Scand. 2019;139(3):208–219. DOI: 10.1111/ane.13045.
61. Schaad U.B., Mütterlein R., Goffin H.; BV-Child Study Group. Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a double-blind, placebo-controlled multicenter study. Chest. 2002;122(6):2042–2049. DOI: 10.1378/chest.122.6.2042.
62. Feleszko W., Jaworska J., Rha R.D. et al. Probiotic-induced suppression of allergic sensitization and airway inflammation is associated with an increase of T regulatory-dependent mechanisms in a murine model of asthma. Clin Exp Allergy. 2007;37(4):498–505. DOI: 10.1111/j.1365-2222.2006.02629.x.
63. Kearney S.C., Dziekiewicz M., Feleszko W. Immunoregulatory and immunostimulatory responses of bacterial lysates in respiratory infections and asthma. Ann Allergy Asthma Immunol. 2015;114(5):364–369. DOI: 10.1016/j.anai.2015.02.008.
64. Yin J., Xu B., Zeng X., Shen K. Broncho-Vaxom in pediatric recurrent respiratory tract infections: A systematic review and meta-analysis. Int Immunopharmacol. 2018;54:198–209. DOI: 10.1016/j.intimp.2017.10.032.
65. De Boer G.M., Żółkiewicz J., Strzelec K.P. et al. Bacterial lysate therapy for the prevention of wheezing episodes and asthma exacerbations: a systematic review and meta-analysis. Eur Respir Rev. 2020;29(158):190175. DOI: 10.1183/16000617.0175-2019.
66. Emeryk A., Bartkowiak-Emeryk M., Raus Z. et al. Mechanical bacterial lysate administration prevents exacerbation in allergic asthmatic children-The EOLIA study. Pediatr Allergy Immunol. 2018;29(4):394–401. DOI: 10.1111/pai.12894.
67. Cazzola M., Capuano A., Rogliani P., Matera M.G. Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. Curr Opin Pharmacol. 2012;12(3):300–308. DOI: 10.1016/j.coph.2012.01.019.
68. Hsu C.Y., Chiu S.W., Hong K.S. et al. Folic Acid in Stroke Prevention in Countries without Mandatory Folic Acid Food Fortification: A Meta-Analysis of Randomized Controlled Trials. J Stroke. 2018;20(1):99–109. DOI: 10.5853/jos.2017.01522.
69. Kok D.E., Steegenga W.T., Smid E.J. et al. Bacterial folate biosynthesis and colorectal cancer risk: more than just a gut feeling. Crit Rev Food Sci Nutr. 2020;60(2):244–256. DOI: 10.1080/10408398.2018.1522499.
70. Vogel R.F., Pavlovic M., Ehrmann M.A. et al. Genomic analysis reveals Lactobacillus sanfranciscensis as stable element in traditional sourdoughs. Microb Cell Fact. 2011;10 Suppl 1(Suppl 1):S6. DOI: 10.1186/1475-2859-10-S1-S6.
71. Mohammad M.A., Molloy A., Scott J., Hussein L. Plasma cobalamin and folate and their metabolic markers methylmalonic acid and total homocysteine among Egyptian children before and after nutritional supplementation with the probiotic bacteria Lactobacillus acidophilus in yoghurt matrix. Int J Food Sci Nutr. 2006;57(7–8):470–480. DOI: 10.1080/09637480600968735.
72. Camelo-Castillo A., Rivera-Caravaca J.M., Orenes-Piñero E. et al. Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications. J Clin Med. 2021;10(4):715. DOI: 10.3390/jcm10040715.
73. Zhang Y., Ma C., Zhao J. et al. Lactobacillus casei Zhang and vitamin K2 prevent intestinal tumorigenesis in mice via adiponectin-elevated different signaling pathways. Oncotarget. 2017;8(15):24719–24727. DOI: 10.18632/oncotarget.15791.
74. Liu Y., Hou Y., Wang G. et al. Gut Microbial Metabolites of Aromatic Amino Acids as Signals in Host-Microbe Interplay. Trends Endocrinol Metab. 2020;31(11):818–834. DOI: 10.1016/j.tem.2020.02.012.
75. Devlin A.S., Marcobal A., Dodd D. et al. Modulation of a Circulating Uremic Solute via Rational Genetic Manipulation of the Gut Microbiota. Cell Host Microbe. 2016;20(6):709–715. DOI: 10.1016/j.chom.2016.10.021.
76. Cortés-Martín A., Selma M.V., Tomás-Barberán F.A. et al. Wh ere to Look into the Puzzle of Polyphenols and Health? The Postbiotics and Gut Microbiota Associated with Human Metabotypes. Mol Nutr Food Res. 2020;64(9):e1900952. DOI: 10.1002/mnfr.201900952.
77. Espín J.C., González-Sarrías A., Tomás-Barberán F.A. The gut microbiota: A key factor in the therapeutic effects of (poly)phenols. Biochem Pharmacol. 2017;139:82–93. DOI: 10.1016/j.bcp.2017.04.033.
78. Xia B., Shi X.C., Xie B.C. et al. Urolithin A exerts antiobesity effects through enhancing adipose tissue thermogenesis in mice. PLoS Biol. 2020;18(3):e3000688. DOI: 10.1371/journal.pbio.3000688.
79. Andreux P.A., Blanco-Bose W., Ryu D. et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab. 2019;1(6):595–603. DOI: 10.1038/s42255-019-0073-4.
80. Yoshikata R., Myint K.Z.Y., Ohta H. Effects of Equol Supplement on Bone and Cardiovascular Parameters in Middle-Aged Japanese Women: A Prospective Observational Study. J Altern Complement Med. 2018;24(7):701–708. DOI: 10.1089/acm.2018.0050.
81. Tousen Y., Ezaki J., Fujii Y. et al. Natural S-equol decreases bone resorption in postmenopausal, non-equol-producing Japanese women: a pilot randomized, placebo-controlled trial. Menopause. 2011;18(5):563–574. DOI: 10.1097/gme.0b013e3181f85aa7.
82. Chalamaiah M., Yu W., Wu J. Immunomodulatory and anticancer protein hydrolysates (peptides) from food proteins: A review. Food Chem. 2018;245:205–222. DOI: 10.1016/j.foodchem.2017.10.087.
83. Korhonen H., Pihlanto A.A. Bioactive peptides: Productionand functionality. Int Dairy J. 2006;16:945–960. DOI: 10.1016/J.IDAIRYJ.2005.10.012.
84. Möller N.P., Scholz-Ahrens K.E., Roos N., Schrezenmeir J. Bioactive peptides and proteins from foods: indication for health effects. Eur J Nutr. 2008;47(4):171–182. DOI: 10.1007/s00394-008-0710-2.
85. Arpaia N., Campbell C., Fan X. et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504(7480):451–455. DOI: 10.1038/nature12726.
86. Jensen G.S., Benson K.F., Carter S.G., Endres J.R. GanedenBC30 cell wall and metabolites: anti-inflammatory and immune modulating effects in vitro. BMC Immunol. 2010;11:15. DOI: 10.1186/1471-2172-11-15.
87. Hoarau C., Martin L., Faugaret D. et al. Supernatant from bifidobacterium differentially modulates transduction signaling pathways for biological functions of human dendritic cells. PLoS One. 2008;3(7):e2753. DOI: 10.1371/journal.pone.0002753.
88. Ménard S., Laharie D., Asensio C. et al. Bifidobacterium breve and Streptococcus thermophilus secretion products enhance T helper 1 immune response and intestinal barrier in mice. Exp Biol Med (Maywood). 2005;230(10):749–756. DOI: 10.1177/153537020523001008.
89. Cousin F.J., Jouan-Lanhouet S., Dimanche-Boitrel M.T. et al. Milk fermented by Propionibacterium freudenreichii induces apoptosis of HGT-1 human gastric cancer cells. PLoS One. 2012;7(3):e31892. DOI: 10.1371/journal.pone.0031892.
90. Salva S., Tiscornia I., Gutiérrez F. et al. Lactobacillus rhamnosus postbiotic-induced immunomodulation as safer alternative to the use of live bacteria. Cytokine. 2021;146:155631. DOI: 10.1016/j.cyto.2021.155631.
91. Rigo-Adrover M.D.M., Knipping K., Garssen J. et al. Prevention of Rotavirus Diarrhea in Suckling Rats by a Specific Fermented Milk Concentrate with Prebiotic Mixture. Nutrients. 2019;11(1):189. DOI: 10.3390/nu11010189.
92. Nocerino R., Paparo L., Terrin G. et al. Cow's milk and rice fermented with Lactobacillus paracasei CBA L74 prevent infectious diseases in children: A randomized controlled trial. Clin Nutr. 2017;36(1):118–125. DOI: 10.1016/j.clnu.2015.12.004.
93. Malagón-Rojas J.N., Mantziari A., Salminen S., Szajewska H. Postbiotics for Preventing and Treating Common Infectious Diseases in Children: A Systematic Review. Nutrients. 2020;12(2):389. DOI: 10.3390/nu12020389.
94. Morisset M., Aubert-Jacquin C., Soulaines P. et al. A non-hydrolyzed, fermented milk formula reduces digestive and respiratory events in infants at high risk of allergy. Eur J Clin Nutr. 2011;65(2):175–183. DOI: 10.1038/ejcn.2010.250.
95. Хавкин А.И., Ковтун Т.А., Макаркин Д.В., Федотова О.Б. Кисломолочные продукты и здоровье ребенка. Российский вестник перинатологии и педиатрии. 2020;65(6):155–165. [Khavkin A.I., Kovtun T.A., Makarkin D.V., Fedotova O.B. Fermented Milk Products and Child Health. Russian Bulletin of perinatology and pediatrics. 2020;65(6):155–165 (in Russ.)]. DOI: 10.21508/1027-4065-2020-65-6-155-165.
96. Хавкин А.И., Федотова О.Б., Волынец Г.В. и др. Результаты проспективного сравнительного открытого рандомизированного исследования по изучению эффективности йогурта, обогащенного пребиотиками и пробиотиками, у детей раннего возраста, перенесших острую респираторную инфекцию. Вопросы детской диетологии. 2019;17(1):29–37. [Khavkin А.I., Fedotova O.B., Volynets G.V. et al. The results of a prospective comparative openlabel randomised study of the effectiveness of a probiotic- and prebiotic-fortified yogurt in small children after an acute respiratory infection. Pediatric Nutrition. 2019;17(1):29–37 (in Russ.)]. DOI: 10.20953/1727-5784-2019-1-29-37.
2. Butel M.J., Waligora-Dupriet A.J., Wydau-Dematteis S. The developing gut microbiota and its consequences for health. J Dev Orig Health Dis. 2018;9(6):590–597. DOI: 10.1017/S2040174418000119.
3. Preveden T., Scarpellini E., Milić N. et al. Gut microbiota changes and chronic hepatitis C virus infection. Expert Rev Gastroenterol Hepatol. 2017;11(9):813–819. DOI: 10.1080/17474124.2017.1343663.
4. Scarpellini E., Basilico M., Rinninella E. et al. Probiotics and gut health. Minerva Gastroenterol (Torino). 2021;67(4):314–325. DOI: 10.23736/S2724-5985.21.02910-7.
5. Jia W., Xie G., Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018;15(2):111–128. DOI: 10.1038/nrgastro.2017.119.
6. Daniali M., Nikfar S., Abdollahi M. Antibiotic resistance propagation through probiotics. Expert Opin Drug Metab Toxicol. 2020;16(12):1207–1215. DOI: 10.1080/17425255.2020.1825682.
7. Żółkiewicz J., Marzec A., Ruszczyński M., Feleszko W. Postbiotics-A Step Beyond Pre- and Probiotics. Nutrients. 2020;12(8):2189. DOI: 10.3390/nu12082189.
8. Liberati A., Altman D.G., Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. DOI: 10.1371/journal.pmed.1000100.
9. Arumugam M., Raes J., Pelletier E. et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174–180. DOI: 10.1038/nature09944.
10. Tap J., Mondot S., Levenez F. et al. Towards the human intestinal microbiota phylogenetic core. Environ Microbiol. 2009;11(10):2574–2584. DOI: 10.1111/j.1462-2920.2009.01982.x.
11. Zhuang L., Chen H., Zhang S. et al. Intestinal Microbiota in Early Life and Its Implications on Childhood Health. Genomics Proteomics Bioinformatics. 2019;17(1):13–25. DOI: 10.1016/j.gpb.2018.10.002.
12. Yatsunenko T., Rey F.E., Manary M.J. et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222–227. DOI: 10.1038/nature11053.
13. Biagi E., Franceschi C., Rampelli S. et al. Gut Microbiota and Extreme Longevity. Curr Biol. 2016;26(11):1480–1485. DOI: 10.1016/j.cub.2016.04.016.
14. Rooks M.G., Garrett W.S. Gut microbiota, metabolites and host immunity. Nat Rev Immunol. 2016;16(6):341–352. DOI: 10.1038/nri.2016.42.
15. Maynard C.L., Elson C.O., Hatton R.D., Weaver C.T. Reciprocal interactions of the intestinal microbiota and immune system. Nature. 2012;489(7415):231–241. DOI: 10.1038/nature11551.
16. Abenavoli L., Scarpellini E., Colica C. et al. Gut Microbiota and Obesity: A Role for Probiotics. Nutrients. 2019;11(11):2690. DOI: 10.3390/nu11112690.
17. Li H.Y., Zhou D.D., Gan R.Y. et al. Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics on Metabolic Diseases Targeting Gut Microbiota: A Narrative Review. Nutrients. 2021;13(9):3211. DOI: 10.3390/nu13093211.
18. Vallianou N., Stratigou T., Christodoulatos G.S. et al. Probiotics, Prebiotics, Synbiotics, Postbiotics, and Obesity: Current Evidence, Controversies, and Perspectives. Curr Obes Rep. 2020;9(3):179–192. DOI: 10.1007/s13679-020-00379-w.
19. Salminen S., Collado M.C., Endo A. et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18(9):649–667. DOI: 10.1038/s41575-021-00440-6.
20. Tsilingiri K., Rescigno M. Postbiotics: what else? Benef Microbes. 2013;4(1):101–107. DOI: 10.3920/BM2012.0046.
21. Aguilar-Toalá J.E., Arioli S., Behare P. et al. Postbiotics — when simplification fails to clarify. Nat Rev Gastroenterol Hepatol. 2021;18(11):825–826. DOI: 10.1038/s41575-021-00521-6.
22. Qin J., Li R., Raes J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65. DOI: 10.1038/nature08821.
23. Amaretti A., di Nunzio M., Pompei A. et al. Antioxidant properties of potentially probiotic bacteria: in vitro and in vivo activities. Appl Microbiol Biotechnol. 2013;97(2):809–817. DOI: 10.1007/s00253-012-4241-7.
24. Khodaii Z., Ghaderian S.M.H., Natanzi M.M. Probiotic Bacteria and their Supernatants Protect Enterocyte Cell Lines fr om Enteroinvasive Escherichia coli (EIEC) Invasion. Int J Mol Cell Med. 2017;6(3):183–189. DOI: 10.22088/acadpub.BUMS.6.3.183.
25. Izuddin W.I., Loh T.C., Foo H.L. et al. Postbiotic L. plantarum RG14 improves ruminal epithelium growth, immune status and upregulates the intestinal barrier function in post-weaning lambs. Sci Rep. 2019;9(1):9938. DOI: 10.1038/s41598-019-46076-0.
26. West C., Stanisz A.M., Wong A., Kunze W.A. Effects of Saccharomyces cerevisiae or boulardii yeasts on acute stress induced intestinal dysmotility. World J Gastroenterol. 2016;22(48):10532–10544. DOI: 10.3748/wjg.v22.i48.10532.
27. Canonici A., Siret C., Pellegrino E. et al. Saccharomyces boulardii improves intestinal cell restitution through activation of the α2β1 integrin collagen receptor. PLoS One. 2011;6(3):e18427. DOI: 10.1371/journal.pone.0018427.
28. Singh P., Saini P. Food and Health Potentials of Exopolysaccharides Derived from Lactobacilli. Microbiol Res J Int. 2017;22:1–14. DOI: 10.9734/mrji/2017/36935.
29. Makino S., Sato A., Goto A. et al. Enhanced natural killer cell activation by exopolysaccharides derived from yogurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1. J Dairy Sci. 2016;99(2):915–923. DOI: 10.3168/jds.2015-10376.
30. Lei X., Zhang H., Hu Z. et al. Immunostimulatory activity of exopolysaccharides from probiotic Lactobacilli casei WXD030 strain as a novel adjuvant in vitro and in vivo. Food Agric Immunol. 2018;29:1086–1105. DOI: 10.1080/09540105.2018.1513994.
31. Li W., Ji J., Chen X. et al. Structural elucidation and antioxidant activities of exopolysaccharides from Lactobacillus helveticus MB2-1. Carbohydr Polym. 2014;102:351–359. DOI: 10.1016/j.carbpol.2013.11.053.
32. Khalil E.S., Abd Manap M.Y., Mustafa S. et al. Probiotic Properties of Exopolysaccharide-Producing Lactobacillus Strains Isolated from Tempoyak. Molecules. 2018;23(2):398. DOI: 10.3390/molecules23020398.
33. Uchida M., Ishii I., Inoue C. et al. Kefiran reduces atherosclerosis in rabbits fed a high cholesterol diet. J Atheroscler Thromb. 2010;17(9):980–988. DOI: 10.5551/jat.4812.
34. Li B., Cai Y., Qi C. et al. Orally administered particulate beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer. Clin Cancer Res. 2010;16(21):5153–5164. DOI: 10.1158/1078-0432.CCR-10-0820.
35. Vetvicka V., Vetvickova J. Glucan supplementation enhances the immune response against an influenza challenge in mice. Ann Transl Med. 2015;3(2):22. DOI: 10.3978/j.issn.2305-5839.2015.01.08.
36. Garai-Ibabe G., Dueñas M.T., Irastorza A. et al. Naturally occurring 2-substituted (1,3)-beta-D-glucan producing Lactobacillus suebicus and Pediococcus parvulus strains with potential utility in the production of functional foods. Bioresour Technol. 2010;101(23):9254–9263. DOI: 10.1016/j.biortech.2010.07.050.
37. Morifuji M., Ichikawa S., Kitade M. et al. Exopolysaccharides from milk fermented by lactic acid bacteria enhance dietary carotenoid bioavailability in humans in a randomized crossover trial and in rats. Am J Clin Nutr. 2020;111(4):903–914. DOI: 10.1093/ajcn/nqaa020.
38. Jesenak M., Urbancek S., Majtan J. et al. β-Glucan-based cream (containing pleuran isolated from pleurotus ostreatus) in supportive treatment of mild-to-moderate atopic dermatitis. J Dermatolog Treat. 2016;27(4):351–354. DOI: 10.3109/09546634.2015.1117565.
39. Kullisaar T., Zilmer M., Mikelsaar M. et al. Two antioxidative lactobacilli strains as promising probiotics. Int J Food Microbiol. 2002;72(3):215–224. DOI: 10.1016/s0168-1605(01)00674-2.
40. Kim H.S., Chae H.S., Jeong S.G. et al. In vitro Antioxidative Properties of Lactobacilli. Asian-Australas J Anim Sci. 2005;19:262–265. DOI: 10.5713/ajas.2006.262.
41. Izuddin W.I., Humam A.M., Loh T.C. et al. Dietary Postbiotic Lactobacillus plantarum Improves Serum and Ruminal Antioxidant Activity and Upregulates Hepatic Antioxidant Enzymes and Ruminal Barrier Function in Post-Weaning Lambs. Antioxidants (Basel). 2020;9(3):250. DOI: 10.3390/antiox9030250.
42. LeBlanc J.G., del Carmen S., Miyoshi A. et al. Use of superoxide dismutase and catalase producing lactic acid bacteria in TNBS induced Crohn's disease in mice. J Biotechnol. 2011;151(3):287–293. DOI: 10.1016/j.jbiotec.2010.11.008.
43. Moser S.A., Savage D.C. Bile salt hydrolase activity and resistance to toxicity of conjugated bile salts are unrelated properties in lactobacilli. Appl Environ Microbiol. 2001;67(8):3476–3480. DOI: 10.1128/AEM.67.8.3476-3480.2001.
44. Allain T., Chaouch S., Thomas M. et al. Bile Salt Hydrolase Activities: A Novel Target to Screen Anti-Giardia Lactobacilli? Front Microbiol. 2018;9:89. DOI: 10.3389/fmicb.2018.00089.
45. Van Langevelde P., van Dissel J.T., Ravensbergen E. et al. Antibiotic-induced release of lipoteichoic acid and peptidoglycan from Staphylococcus aureus: quantitative measurements and biological reactivities. Antimicrob Agents Chemother. 1998;42(12):3073–3078. DOI: 10.1128/AAC.42.12.3073.
46. Kaji R., Kiyoshima-Shibata J., Nagaoka M. et al. Bacterial teichoic acids reverse predominant IL-12 production induced by certain lactobacillus strains into predominant IL-10 production via TLR2-dependent ERK activation in macrophages. J Immunol. 2010;184(7):3505–3513. DOI: 10.4049/jimmunol.0901569.
47. Zadeh M., Khan M.W., Goh Y.J. et al. Induction of intestinal pro-inflammatory immune responses by lipoteichoic acid. J Inflamm (Lond). 2012;9:7. DOI: 10.1186/1476-9255-9-7.
48. Schauber J., Gallo R.L. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol. 2009;124(3 Suppl 2):R13–18. DOI: 10.1016/j.jaci.2009.07.014.
49. Wang Z., MacLeod D.T., Di Nardo A. Commensal bacteria lipoteichoic acid increases skin mast cell antimicrobial activity against vaccinia viruses. J Immunol. 2012;189(4):1551–1558. DOI: 10.4049/jimmunol.1200471.
50. Okamoto M., Ohe G., Oshikawa T. et al. Enhancement of anti-cancer immunity by a lipoteichoic-acid-related molecule isolated from a penicillin-killed group A Streptococcus. Cancer Immunol Immunother. 2001;50(8):408–416. DOI: 10.1007/s002620100207.
51. Lebeer S., Claes I.J., Vanderleyden J. Anti-inflammatory potential of probiotics: lipoteichoic acid makes a difference. Trends Microbiol. 2012;20(1):5–10. DOI: 10.1016/j.tim.2011.09.004.
52. Lee C., Kim B.G., Kim J.H. et al. Sodium butyrate inhibits the NF-kappa B signaling pathway and histone deacetylation, and attenuates experimental colitis in an IL-10 independent manner. Int Immunopharmacol. 2017;51:47–56. DOI: 10.1016/j.intimp.2017.07.023.
53. Lührs H., Gerke T., Müller J.G. et al. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol. 2002;37(4):458–466. DOI: 10.1080/003655202317316105.
54. Kasahara K., Krautkramer K.A., Org E. et al. Interactions between Roseburia intestinalis and diet modulate atherogenesis in a murine model. Nat Microbiol. 2018;3(12):1461–1471. DOI: 10.1038/s41564-018-0272-x.
55. Aoki R., Kamikado K., Suda W. et al. A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation. Sci Rep. 2017;7:43522. DOI: 10.1038/srep43522.
56. Frost G., Sleeth M.L., Sahuri-Arisoylu M. et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun. 2014;5:3611. DOI: 10.1038/ncomms4611.
57. Fukuda S., Toh H., Taylor T.D. et al. Acetate-producing bifidobacteria protect the host from enteropathogenic infection via carbohydrate transporters. Gut Microbes. 2012;3(5):449–454. DOI: 10.4161/gmic.21214.
58. Bush R.S., Milligan L.P. Study of the mechanism of inhibition of ketogenesis by propionate in bovine liver. Can J Anim Sci. 1971;51:121–127. DOI: 10.4141/CJAS71-016.
59. Tedelind S., Westberg F., Kjerrulf M., Vidal A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol. 2007;13(20):2826–2832. DOI: 10.3748/wjg.v13.i20.2826.
60. Melbye P., Olsson A., Hansen T.H. et al. Short-chain fatty acids and gut microbiota in multiple sclerosis. Acta Neurol Scand. 2019;139(3):208–219. DOI: 10.1111/ane.13045.
61. Schaad U.B., Mütterlein R., Goffin H.; BV-Child Study Group. Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a double-blind, placebo-controlled multicenter study. Chest. 2002;122(6):2042–2049. DOI: 10.1378/chest.122.6.2042.
62. Feleszko W., Jaworska J., Rha R.D. et al. Probiotic-induced suppression of allergic sensitization and airway inflammation is associated with an increase of T regulatory-dependent mechanisms in a murine model of asthma. Clin Exp Allergy. 2007;37(4):498–505. DOI: 10.1111/j.1365-2222.2006.02629.x.
63. Kearney S.C., Dziekiewicz M., Feleszko W. Immunoregulatory and immunostimulatory responses of bacterial lysates in respiratory infections and asthma. Ann Allergy Asthma Immunol. 2015;114(5):364–369. DOI: 10.1016/j.anai.2015.02.008.
64. Yin J., Xu B., Zeng X., Shen K. Broncho-Vaxom in pediatric recurrent respiratory tract infections: A systematic review and meta-analysis. Int Immunopharmacol. 2018;54:198–209. DOI: 10.1016/j.intimp.2017.10.032.
65. De Boer G.M., Żółkiewicz J., Strzelec K.P. et al. Bacterial lysate therapy for the prevention of wheezing episodes and asthma exacerbations: a systematic review and meta-analysis. Eur Respir Rev. 2020;29(158):190175. DOI: 10.1183/16000617.0175-2019.
66. Emeryk A., Bartkowiak-Emeryk M., Raus Z. et al. Mechanical bacterial lysate administration prevents exacerbation in allergic asthmatic children-The EOLIA study. Pediatr Allergy Immunol. 2018;29(4):394–401. DOI: 10.1111/pai.12894.
67. Cazzola M., Capuano A., Rogliani P., Matera M.G. Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. Curr Opin Pharmacol. 2012;12(3):300–308. DOI: 10.1016/j.coph.2012.01.019.
68. Hsu C.Y., Chiu S.W., Hong K.S. et al. Folic Acid in Stroke Prevention in Countries without Mandatory Folic Acid Food Fortification: A Meta-Analysis of Randomized Controlled Trials. J Stroke. 2018;20(1):99–109. DOI: 10.5853/jos.2017.01522.
69. Kok D.E., Steegenga W.T., Smid E.J. et al. Bacterial folate biosynthesis and colorectal cancer risk: more than just a gut feeling. Crit Rev Food Sci Nutr. 2020;60(2):244–256. DOI: 10.1080/10408398.2018.1522499.
70. Vogel R.F., Pavlovic M., Ehrmann M.A. et al. Genomic analysis reveals Lactobacillus sanfranciscensis as stable element in traditional sourdoughs. Microb Cell Fact. 2011;10 Suppl 1(Suppl 1):S6. DOI: 10.1186/1475-2859-10-S1-S6.
71. Mohammad M.A., Molloy A., Scott J., Hussein L. Plasma cobalamin and folate and their metabolic markers methylmalonic acid and total homocysteine among Egyptian children before and after nutritional supplementation with the probiotic bacteria Lactobacillus acidophilus in yoghurt matrix. Int J Food Sci Nutr. 2006;57(7–8):470–480. DOI: 10.1080/09637480600968735.
72. Camelo-Castillo A., Rivera-Caravaca J.M., Orenes-Piñero E. et al. Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications. J Clin Med. 2021;10(4):715. DOI: 10.3390/jcm10040715.
73. Zhang Y., Ma C., Zhao J. et al. Lactobacillus casei Zhang and vitamin K2 prevent intestinal tumorigenesis in mice via adiponectin-elevated different signaling pathways. Oncotarget. 2017;8(15):24719–24727. DOI: 10.18632/oncotarget.15791.
74. Liu Y., Hou Y., Wang G. et al. Gut Microbial Metabolites of Aromatic Amino Acids as Signals in Host-Microbe Interplay. Trends Endocrinol Metab. 2020;31(11):818–834. DOI: 10.1016/j.tem.2020.02.012.
75. Devlin A.S., Marcobal A., Dodd D. et al. Modulation of a Circulating Uremic Solute via Rational Genetic Manipulation of the Gut Microbiota. Cell Host Microbe. 2016;20(6):709–715. DOI: 10.1016/j.chom.2016.10.021.
76. Cortés-Martín A., Selma M.V., Tomás-Barberán F.A. et al. Wh ere to Look into the Puzzle of Polyphenols and Health? The Postbiotics and Gut Microbiota Associated with Human Metabotypes. Mol Nutr Food Res. 2020;64(9):e1900952. DOI: 10.1002/mnfr.201900952.
77. Espín J.C., González-Sarrías A., Tomás-Barberán F.A. The gut microbiota: A key factor in the therapeutic effects of (poly)phenols. Biochem Pharmacol. 2017;139:82–93. DOI: 10.1016/j.bcp.2017.04.033.
78. Xia B., Shi X.C., Xie B.C. et al. Urolithin A exerts antiobesity effects through enhancing adipose tissue thermogenesis in mice. PLoS Biol. 2020;18(3):e3000688. DOI: 10.1371/journal.pbio.3000688.
79. Andreux P.A., Blanco-Bose W., Ryu D. et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab. 2019;1(6):595–603. DOI: 10.1038/s42255-019-0073-4.
80. Yoshikata R., Myint K.Z.Y., Ohta H. Effects of Equol Supplement on Bone and Cardiovascular Parameters in Middle-Aged Japanese Women: A Prospective Observational Study. J Altern Complement Med. 2018;24(7):701–708. DOI: 10.1089/acm.2018.0050.
81. Tousen Y., Ezaki J., Fujii Y. et al. Natural S-equol decreases bone resorption in postmenopausal, non-equol-producing Japanese women: a pilot randomized, placebo-controlled trial. Menopause. 2011;18(5):563–574. DOI: 10.1097/gme.0b013e3181f85aa7.
82. Chalamaiah M., Yu W., Wu J. Immunomodulatory and anticancer protein hydrolysates (peptides) from food proteins: A review. Food Chem. 2018;245:205–222. DOI: 10.1016/j.foodchem.2017.10.087.
83. Korhonen H., Pihlanto A.A. Bioactive peptides: Productionand functionality. Int Dairy J. 2006;16:945–960. DOI: 10.1016/J.IDAIRYJ.2005.10.012.
84. Möller N.P., Scholz-Ahrens K.E., Roos N., Schrezenmeir J. Bioactive peptides and proteins from foods: indication for health effects. Eur J Nutr. 2008;47(4):171–182. DOI: 10.1007/s00394-008-0710-2.
85. Arpaia N., Campbell C., Fan X. et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504(7480):451–455. DOI: 10.1038/nature12726.
86. Jensen G.S., Benson K.F., Carter S.G., Endres J.R. GanedenBC30 cell wall and metabolites: anti-inflammatory and immune modulating effects in vitro. BMC Immunol. 2010;11:15. DOI: 10.1186/1471-2172-11-15.
87. Hoarau C., Martin L., Faugaret D. et al. Supernatant from bifidobacterium differentially modulates transduction signaling pathways for biological functions of human dendritic cells. PLoS One. 2008;3(7):e2753. DOI: 10.1371/journal.pone.0002753.
88. Ménard S., Laharie D., Asensio C. et al. Bifidobacterium breve and Streptococcus thermophilus secretion products enhance T helper 1 immune response and intestinal barrier in mice. Exp Biol Med (Maywood). 2005;230(10):749–756. DOI: 10.1177/153537020523001008.
89. Cousin F.J., Jouan-Lanhouet S., Dimanche-Boitrel M.T. et al. Milk fermented by Propionibacterium freudenreichii induces apoptosis of HGT-1 human gastric cancer cells. PLoS One. 2012;7(3):e31892. DOI: 10.1371/journal.pone.0031892.
90. Salva S., Tiscornia I., Gutiérrez F. et al. Lactobacillus rhamnosus postbiotic-induced immunomodulation as safer alternative to the use of live bacteria. Cytokine. 2021;146:155631. DOI: 10.1016/j.cyto.2021.155631.
91. Rigo-Adrover M.D.M., Knipping K., Garssen J. et al. Prevention of Rotavirus Diarrhea in Suckling Rats by a Specific Fermented Milk Concentrate with Prebiotic Mixture. Nutrients. 2019;11(1):189. DOI: 10.3390/nu11010189.
92. Nocerino R., Paparo L., Terrin G. et al. Cow's milk and rice fermented with Lactobacillus paracasei CBA L74 prevent infectious diseases in children: A randomized controlled trial. Clin Nutr. 2017;36(1):118–125. DOI: 10.1016/j.clnu.2015.12.004.
93. Malagón-Rojas J.N., Mantziari A., Salminen S., Szajewska H. Postbiotics for Preventing and Treating Common Infectious Diseases in Children: A Systematic Review. Nutrients. 2020;12(2):389. DOI: 10.3390/nu12020389.
94. Morisset M., Aubert-Jacquin C., Soulaines P. et al. A non-hydrolyzed, fermented milk formula reduces digestive and respiratory events in infants at high risk of allergy. Eur J Clin Nutr. 2011;65(2):175–183. DOI: 10.1038/ejcn.2010.250.
95. Хавкин А.И., Ковтун Т.А., Макаркин Д.В., Федотова О.Б. Кисломолочные продукты и здоровье ребенка. Российский вестник перинатологии и педиатрии. 2020;65(6):155–165. [Khavkin A.I., Kovtun T.A., Makarkin D.V., Fedotova O.B. Fermented Milk Products and Child Health. Russian Bulletin of perinatology and pediatrics. 2020;65(6):155–165 (in Russ.)]. DOI: 10.21508/1027-4065-2020-65-6-155-165.
96. Хавкин А.И., Федотова О.Б., Волынец Г.В. и др. Результаты проспективного сравнительного открытого рандомизированного исследования по изучению эффективности йогурта, обогащенного пребиотиками и пробиотиками, у детей раннего возраста, перенесших острую респираторную инфекцию. Вопросы детской диетологии. 2019;17(1):29–37. [Khavkin А.I., Fedotova O.B., Volynets G.V. et al. The results of a prospective comparative openlabel randomised study of the effectiveness of a probiotic- and prebiotic-fortified yogurt in small children after an acute respiratory infection. Pediatric Nutrition. 2019;17(1):29–37 (in Russ.)]. DOI: 10.20953/1727-5784-2019-1-29-37.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
